These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 33332889)

  • 21. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The patient's experience of gout: new insights to optimize management.
    Dalbeth N; Lindsay K
    Curr Rheumatol Rep; 2012 Apr; 14(2):173-8. PubMed ID: 22198831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of management of gout: a comparison of recent guidelines.
    Khanna PP; FitzGerald J
    Curr Opin Rheumatol; 2015 Mar; 27(2):139-46. PubMed ID: 25611299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing medication adherence in patients with gout: A descriptive correlational study.
    Chua XHJ; Lim S; Lim FP; Lim YNA; He HG; Teng GG
    J Clin Nurs; 2018 Jan; 27(1-2):e213-e222. PubMed ID: 28618105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting.
    Lee S; So MW
    Mod Rheumatol; 2016 Nov; 26(6):950-955. PubMed ID: 27142782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better outcomes for patients with gout.
    Day R; Nguyen A; Graham G; Aung E; Coleshill M; Stocker S
    Inflammopharmacology; 2020 Oct; 28(5):1395-1400. PubMed ID: 32095979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The year in gout: 2012-2013 - a walk through the 2012 ACR Gout Treatment Guidelines.
    Crittenden DB; Pillinger MH
    Bull Hosp Jt Dis (2013); 2013; 71(3):189-93. PubMed ID: 24151943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Is the Evidence for Treat-to-Target Serum Urate in Gout?
    Bursill D; Dalbeth N
    Curr Rheumatol Rep; 2018 Mar; 20(3):11. PubMed ID: 29516287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment.
    Slot O
    Scand J Rheumatol; 2018 May; 47(3):194-197. PubMed ID: 28891365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
    Lawrence A; Scott S; Saparelli F; Greville G; Miller A; Taylor A; Gow P
    J Prim Health Care; 2019 Jul; 11(2):117-127. PubMed ID: 32171354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of gout clinic in a tertiary hospital setting.
    Leonardo N; Lester S; Whittle S; Rischmueller M
    Intern Med J; 2020 Jan; 50(1):117-120. PubMed ID: 31943621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Can We Improve Disease Education in People with Gout?
    Fields TR; Batterman A
    Curr Rheumatol Rep; 2018 Mar; 20(3):12. PubMed ID: 29516200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting.
    Lee S; So MW; Ahn E
    Mod Rheumatol; 2019 Jul; 29(4):662-668. PubMed ID: 29856667
    [No Abstract]   [Full Text] [Related]  

  • 40. The clinical efficacy of urate-lowering therapy in acute gout: a meta-analysis of randomized controlled trials.
    Zhang X; Tang Y; Wang M; Wang D; Li Q
    Clin Rheumatol; 2021 Feb; 40(2):701-710. PubMed ID: 32562072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.